Bilateral prophylactic mastectomy as an option for prevention of contralateral breast cancer

Authors

DOI:

https://doi.org/10.18370/2309-4117.2020.55.72-78

Keywords:

сontralateral breast cancer, prophylactic mastectomy, breast cancer

Abstract

The article discusses the risk factors for contralateral breast cancer and the role of prophylactic bimastectomy in reducing these risks. Breast cancer is the most frequent cancer among women. Several strategies have been implemented to reduce the risk of occurrence and recurrence of breast cancer: lifestyle changes, early detection through diagnosis and screening, chemotherapy, and surgery.

Prophylactic mastectomy is one of the growing strategies to reduce the risk of breast cancer. Evidence suggests that the incidence of prophylactic bimastectomy in patients with unilateral breast cancer is steadily increasing, due not only to cancer case but also with requirements in women to modern quality of life. For women who choose or need to undergo a therapeutic mastectomy, removal of the contralateral breast is often discussed. Although the risk of contralateral breast cancer is relatively low for patients without hereditary genetic mutations with an established primary diagnosis of breast cancer, the total number of women who are at risk of developing contralateral breast cancer has increased markedly over the past few decades. Thus, among the risk factors influencing the occurrence of cancer in the contralateral healthy breast are young women with breast cancer, genetic mutation carriers, strong family history, ductal non-invasive cancer, tumour characteristics, which are indication to bilateral prophylactic mastectomy with immediate breast reconstruction.

However, at the present stage of development oncoplastic and reconstructive breast cancer surgery, in the leading position one of the indications for prophylactic contralateral subcutaneous mastectomy with immediate breast reconstruction – is the patient's desire to preserve aesthetics and femininity. The level of satisfaction among women with bilateral mastectomy and breast reconstruction is higher than in women with unilateral mastectomy and reconstruction. Improvement of reconstructive and surgical techniques for performing contralateral prophylactic mastectomy provides the best aesthetic result among patients. Therefore, the present data requires a more detailed study of this issue and approval in the scientific community.

Author Biographies

D. V. Pominchuk, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; Medical centre “Verum Expert Clinic”, Kyiv

PhD, senior researcher;

Mammologist, oncosurgeon

T. S. Shevchuk, Medical centre “Verum Expert Clinic”, Kyiv

Surgeon

References

  1. DeSantis, C., Ma, J., Bryan, L., Jemal, A. “Breast cancer statistics, 2013.” CA Cancer J Clin 64.1 (2014): 52–62. DOI: 10.3322/caac.21203
  2. DeSantis, C., Howlader, N., Cronin, K.A., Jemal, A. “Breast cancer incidence rates in U.S. women are no longer declining.” Cancer Epidemiol Biomarkers Prev 20.5 (2011): 733–9. DOI: 10.1158/1055-9965.EPI-11-0061
  3. Lee, H.B., Han, W. “Unique Features of Young Age Breast Cancer and Its Management.” J Breast Cancer 17.4 (2014): 301–7. DOI: 10.4048/jbc.2014.17.4.301
  4. Gabriel, C.A., Domchek, S.M. “Breast cancer in young women.” Breast Cancer Res 12.5 (2010): 212. DOI: 10.1186/bcr2647
  5. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.” Int J Cancer 136.5 (2015): E359–E386. DOI: 10.1002/ijc.29210
  6. Darby, S., McGale, P., et al.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). “Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.” Lancet 378.9804 (2011): 1707–16. DOI: 10.1016/S0140-6736(11)61629-2
  7. Gao, X., Fisher, S.G., Emami, B. “Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.” Int J Radiat Oncol Biol Phys 56.4 (2003):1038–45. DOI: 10.1016/s0360-3016(03)00203-7
  8. Nichols, H.B., Berrington de González, A., Lacey, J.V. Jr, et al. “Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.” J Clin Oncol 29.12 (2011): 1564–9. DOI: 10.1200/JCO.2010.32.7395
  9. Siegel, R., Naishadham, D., Jemal, A. “Cancer statistics, 2012.” CA Cancer J Clin 62.1 (2012): 10–29. DOI :10.3322/caac.20138
  10. Lizarraga, I.M., Sugg, S.L., Weigel, R.J., Scott-Conner, C.E. “Review of risk factors for the development of contralateral breast cancer.” Am J Surg 206.5 (2013): 704–8. DOI: 10.1016/j. amjsurg.2013.08.002
  11. Bouchardy, C., Benhamou, S., Fioretta, G., et al. “Risk of second breast cancer according to estrogen receptor status and family history.” Breast Cancer Res Treat 127 (2011): 233–41.
  12. Kheirelseid, E.A., Jumustafa, H., Miller, N., et al. “Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics.” Breast Cancer Res Treat 126.1 (2011): 131–40. DOI: 10.1007/s10549-010-1057-y
  13. Vichapat, V., Garmo, H., Holmqvist, M., et al. “Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population–based study.” J Clin Oncol 30 (2012): 3478–85.
  14. Basu, S.K., Schwartz, C., Fisher, S.G., et al. “Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin’s disease.” Int J Radiat Oncol Biol Phys 72 (2008): 34–40.
  15. Arrington, A.K., Voci, A., Reparaz, L., Fry, W. “Factors and outcomes associated with surgical treatment options of contralateral breast cancer.” Am J Surg 208 (2014): 524–30.
  16. Quan, G., Pommier, S.J., Pommier, R.F. “Incidence and outcomes of contralateral breast cancers.” Am J Surg 195 (2008): 645–50.
  17. Yoon, K.H., Chae, S., Kang, E., et al. “Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer.” J Breast Cancer 22.4 (2019): 587–98. DOI: 10.4048/jbc.2019.22.e47
  18. Shahedi, K., Emanuelsson, M., Wiklund, F., Gronberg, H. “High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.” Cancer 106.6 (2006): 1237–42. DOI: 10.1002/cncr.21753
  19. Tilanus-Linthorst, M.M.A., Alves, C., Seynaeve, C., et al. “Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.” Br J Surg 93 (2006): 961–8. DOI: 10.1002/bjs.5344
  20. Basu, N.N., Barr, L., Ross, G.L., Evans, D.G. “Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.” Int J Surg Oncol 2015 (2015): 901046. DOI: 10.1155/2015/901046
  21. Bhatia, S., Yasui, Y., Robison, L.L., et al. “High risk of subsequent neoplasms continues with extended follow up of childhood Hodgkin’s disease: Report from the late effects study group.” J Clin Oncol 21 (2003): 4386–94.
  22. Vaittinen, P., Hemminki, K. “Risk factors and age-incidence relationships for contralateral breast cancer.” Int J Cancer 88.6 (2000): 998–1002. DOI: 10.1002/1097-0215(20001215)88:6<998::aid-ijc25>3.0.co;2-0
  23. Schaapveld, M., Visser, O., Louwman, W.J., et al. “The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands.” Breast Cancer Res Treat 110.1 (2008): 189–97. DOI: 10.1007/s10549-007-9709-2
  24. Kurian, A.W., McClure, L.A., John, E.M., et al. “Second primary breast cancer occurrence according to hormone receptor status.” J Natl Cancer Inst 101.15 (2009): 1058–65. DOI: 10.1093/jnci/djp181
  25. Narod, SA. “Bilateral breast cancers.” Nat Rev Clin Oncol 11.3 (2014): 157–66. DOI: 10.1038/nrclinonc.2014.3
  26. Walsh, T., King, M.C. “Ten genes for inherited breast cancer.” Cancer Cell 11.2 (2007): 103–5. DOI: 10.1016/j.ccr.2007.01.010
  27. Kuchenbaecker, K.B., Hopper, J.L., Barnes, D.R., et al. “Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.” JAMA 317.23 (2017): 2402–16. DOI: 10.1001/jama.2017.7112
  28. Metcalfe, K., Lynch, H.T., Ghadirian, P., et al. “Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.” J Clin Oncol 22.12 (2004): 2328–35. DOI: 10.1200/JCO.2004.04.033
  29. Narod, S.A., Brunet, J.S., Ghadirian, P., et al. “Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.” Lancet 356.9245 (2000): 1876–81. DOI: 10.1016/s0140-6736(00)03258-x
  30. Gronwald, J., Tung, N., Foulkes, W.D., et al. “Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.” Int J Cancer 118.9 (2006): 2281–4. DOI: 10.1002/ijc.21536
  31. Graeser, M., Engel, C., Rhiem, K., et al. “Contralateral breast cancer risk in BRCA1 and BRCA2 mutation сarriers.” Journal of clinical oncology 27 (2009): 5887–92. DOI: 10.1200/JCO.2008.19.9430
  32. Metcalfe, K., Gershman, S., Lynch, H.T., et al. “Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.” Br J Cancer 104.9 (2011): 1384–92. DOI: 10.1038/bjc.2011.120
  33. Laitman, Y., Vaisman, Y., Feldman, D., et al. “Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.” Clin Genet 85.1 (2014): 68–71. DOI: 10.1111/cge.12149
  34. Pierce, L.J., Strawderman, M., Narod, S.A., et al. “Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.” J Clin Oncol 18.19 (2000): 3360–9. DOI: 10.1200/JCO.2000.18.19.3360
  35. Chappuis, P., Kapusta, L., Bégin, L., et al. “Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer.” Journal of clinical oncology 18 (2000): 4045–52. DOI: 10.1200/JCO.2000.18.24.4045
  36. Malone, K.E., Begg, C.B., Haile, R.W., et al. {Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.” J Clin Oncol 28.14 (2010): 2404–10. DOI: 10.1200/JCO.2009.24.2495
  37. Domchek, S.M., Friebel, T.M., Singer, C.F., et al. “Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality.” JAMA 304.9 (2010): 967–75. DOI: 10.1001/jama.2010.1237
  38. Mavaddat, N., Peock, S., Frost, D., et al. “Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.” J Natl Cancer Inst 105.11 (2013): 812–22. DOI: 10.1093/jnci/djt095
  39. Metcalfe, K.A., Birenbaum-Carmeli, D., Lubinski, J., et al. “International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.” Int J Cancer 122.9 (2008): 2017–22. DOI: 10.1002/ijc.23340
  40. Lodder, L.N., et al. “One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).” Breast Cancer Res Treat 73 (2002): 97–112. DOI: 10.1023A:1015269620265
  41. Evans, D.G., Ingham, S.L., Baildam, A., et al. “Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.” Breast Cancer Res Treat 140.1 (2013): 135–42. DOI: 10.1007/s10549-013-2583-1
  42. Singer, C.F., Muhr, D., Rappaport, C., et al. “Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.” Clin Genet 85.1 (2014): 72–5. DOI: 10.1111/cge.12216
  43. King, T.A., Sakr, R., Patil, S., et al. “Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.” J Clin Oncol 29.16 (2011): 2158–64. DOI: 10.1200/JCO.2010.29.4041
  44. Zhang, S., Phelan, C.M., Zhang, P., et al. “Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.” Cancer Res 68.7 (2008): 2154–7. DOI: 10.1158/0008-5472.CAN-07-5187
  45. Mellemkjaer, L., Dahl, C., Olsen, J.H., et al. “Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.” Br J Cancer 98.4 (2008): 728–33. DOI:10.1038/sj.bjc.6604228
  46. Narod, S.A. “Testing for CHEK2 in the cancer genetics clinic: ready for prime time?” Clin Genet 78.1 (2010): 1–7. DOI: 10.1111/j.1399-0004.2010.01402.x
  47. Reiner, A.S., John, E.M., Brooks, J.D., et al. “Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.” J Clin Oncol 31.4 (2013): 433–9. DOI: 10.1200/JCO.2012.43.2013
  48. Miller, M.E., Muhsen, S., Olcese, C., et al. “Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?” Annals of Surgical Oncology 24.10 (2017): 2889–97. DOI: 10.1245/s10434-017-5931-2
  49. Claus, E.B., Stowe, M., Carter, D., Holford, T. “The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry.” The Breast 12.6 (2003): 451–6. DOI: 10.1016/S0960-9776(03)00152-8
  50. Saltzman, B.S., Malone, K.E., McDougall, J.A., et al. “Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.” Breast Cancer Res Treat 135.3 (2012): 849–55. DOI: 10.1007/s10549-012-2183-5
  51. Swain, S.M., Wilson, J.W., Mamounas, E.P., et al. “Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer.” JNCI 96.7 (2004): 516–23. DOI: 10.1093/jnci/djh097
  52. Arpino, G., Weiss, H.L., Clark, G.M., et al. “Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.” J Clin Oncol 23 (2005): 4687–94.
  53. Vogel, V.G., Costantino, J.P., Wickerham, D.L., et al. “Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.” Cancer Prev Res (Phila) 3.6 (2010): 696–706. DOI: 10.1158/1940-6207.CAPR-10-0076
  54. Bessonova, L., Taylor, T.H., Mehta, R.S., et al. “Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.” Cancer Epidemiol Biomarkers Prev 20.2 (2011): 389–96. DOI: 10.1158/1055-9965.EPI-10-1016
  55. Ghosh, K., Hartmann, L.C. “Current status of prophylactic mastectomy.” Oncology (Williston Park) 16 (2002): 1319–25.
  56. Manning, A.T., Wood, C., Eaton, A., et al. “Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.” Br J Surg 102.11 (2015): 1354–9. DOI: 10.1002/bjs.9884
  57. Warren Peled, A., Foster, R.D., Stover, A.C., et al. “Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts.” Ann Surg Oncol 19.11 (2012): 3402–9. DOI: 10.1245/s10434-012-2362-y
  58. Han, E., Johnson, N., Glissmeyer, M., et al. “Increasing incidence of bilateral mastectomies: the patient perspective.” Am J Surg 201 (2011): 615–8.
  59. Tuttle, T.M., Habermann, E.B., Grund, E.H., et al. “Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.” J Clin Oncol 25.33 (2007): 5203–9. DOI: 10.1200/JCO.2007.12.3141
  60. Wong, S.M., Freedman, R.A., Sagara, Y., et al. “Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.” Ann Surg 265.3 (2017): 581–9. DOI: 10.1097/SLA.0000000000001698
  61. Rebbeck, T.R., Friebel, T., Lynch, H.T., et al. “Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.” J Clin Oncol 22.6 (2004): 1055–62. DOI: 10.1200/JCO.2004.04.188
  62. McDonnell, S.K., Schaid, D.J., Myers, J.L., et al. “Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.” J Clin Oncol 19.19 (2001): 3938–43. DOI: 10.1200/JCO.2001.19.19.3938
  63. Evans, D.G., Baildam, A.D., Anderson, E., et al. “Risk reducing mastectomy: outcomes in 10 European centres.” J Med Genet 46.4 (2009): 254–8. DOI: 10.1136/jmg.2008.062232
  64. Boughey, J.C., Attai, D.J., Chen, S.L., et al. “Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks.” Ann Surg Oncol 23 (2016): 3100–5. DOI: 10.1245/s10434-016-5443-5
  65. Peralta, E.A., Ellenhorn, J.D., Wagman, L.D., et al. “Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer.” Am J Surg 180.6 (2000): 439–45. DOI: 10.1016/s0002-9610(00)00505-5
  66. Hartmann, L.C., Schaid, D.J., Woods, J.E., et al. “Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.” N Engl J Med 340.2 (1999): 77–84. DOI: 10.1056/NEJM199901143400201
  67. Geiger, A.M., Yu, O., Herrinton, L.J., et al. “A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.” Arch Intern Med 165.5 (2005): 516–20. DOI: 10.1001/archinte.165.5.516

Downloads

Published

2020-11-30

How to Cite

Pominchuk, D. V., & Shevchuk, T. S. (2020). Bilateral prophylactic mastectomy as an option for prevention of contralateral breast cancer. REPRODUCTIVE ENDOCRINOLOGY, (55), 72–78. https://doi.org/10.18370/2309-4117.2020.55.72-78

Issue

No. 55 (2020)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2020 D. V. Pominchuk, T. S. Shevchuk

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.